“…The antibodies applied were antiadenomatous polyposis coli (APC; monoclonal mouse anti-recombinant APC, clone CC-1, diluted 1:50, Merck) for oligodendrocytes [8], anti-CD3 (polyclonal rabbit antihuman, diluted 1:1,000, Dako, Hamburg, Germany) for T lymphocytes, anti-CD45R/B220 (monoclonal rat antimouse biotinylated, clone RA3-6B2, diluted 1:1,000, BD Biosciences Pharmingen, Erembodegem, Belgium) for B lymphocytes, anti-CD107b (monoclonal rat anti-mouse biotinylated, clone M3/84, diluted 1:400, Serotec, Oxford, UK) for microglia/macrophages [1,34,65], anti-GFAP (polyclonal rabbit anti-cow, diluted 1:1,000, Dako) for astrocytes, anti-MBP (polyclonal rabbit anti-human, diluted 1:800, Chemicon Europe, Hofheim/Taunus, Germany) for myelin, and anti-TMEV (polyclonal rabbit anti-TMEV capsid protein VP1, diluted 1:2,000 [36]). In MMP-or mock-injected animals, the number of CD107b-, CD3-, CD45R-, APC-, and GFAP-positive cells per CCP was counted.…”